Samuil Umansky, MD, PhD, DrSci, co-founded DiamiR to develop non-invasive, accurate diagnostic tests for early detection of neurodegenerative diseases. He serves as the chief scientific officer (CSO) and president of the company. Previously, Dr. Umansky co-founded and served as the CSO and President of Xenomics (now TrovaGene, NASDAQ: TROV), served as the CSO of LXR Biotechnology, and was a professor at the Institute of Biological Physics of the USSR Academy of Sciences.

He conducted pioneering studies on DNA degradation during apoptosis. The analysis of cell-free nucleic acids has been a major focus of Dr. Umansky’s research over the last 20 years. Dr. Umansky developed new methods for detection and analysis of small nucleic acids in bodily fluids, and invented transrenal-DNA/RNA technology for prenatal genetic testing, tumor diagnostics and monitoring, transplantation monitoring, and infectious disease diagnostics. He has published over 160 peer-reviewed articles, and is a co-inventor on more than 70 patents and patent applications.